Skip to main content
Top
Published in: Radiation Oncology 1/2014

Open Access 01-12-2014 | Research

Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Authors: Xiaoli Zhang, Minghuan LI, Xue Meng, Li Kong, Yan Zhang, Guangsheng Wei, Xiqin Zhang, Fang Shi, Man Hu, Guoli Zhang, Jinming Yu

Published in: Radiation Oncology | Issue 1/2014

Login to get access

Abstract

Background

Since there is high local failure and poor survival for unresectable esophageal squamous cell carcinoma (ESCC), the necessity of elective node irradiation is controversial. The purpose of this study was to investigate the failure patterns and survival in patients with locally advanced ESCC receiving involved-field irradiation (IFI).

Methods

A retrospective study was preformed on the clinical records of patients with locally advanced ESCC, who have received IFI with concurrent chemotherapy between January 2003 and January 2009. Comparing the target volume and first sites of failure, patterns of failure were defined as in-field, out-of-field regional lymph node and distant failure. The survivals were analyzed by different patterns of failure.

Results

Eighty patients were included in our study. With a median follow-up of 52.6 months, failures were observed in 76 patients. In-field recurrence, distant metastasis, and out-of-field regional failure were seen in 53.75%, 41.25%, 30% patients, respectively. There were significant differences in OS for patients with and without in-field (median OS 14.2 vs.17.4 m, P = 0.01)or distant failure(13.2 vs.15.9 m, P ≤ 0.0001), but not for out-of-field regional lymph node failure(both 14.5 m, P = 0.665).

Conclusions

The solitary regional nodal failure of out-of-field was acceptable in advanced ESCC patients treated with IFI. In-field and distant failures remained the predominant patterns and negatively impacted survival more significantly. Further investigation is needed to establish the optimal radiotherapy field for these patients at advanced stage.
Appendix
Available only for authorised users
Literature
2.
go back to reference Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA 1999, 281: 1623-1627.CrossRefPubMed Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV, Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA 1999, 281: 1623-1627.CrossRefPubMed
3.
go back to reference Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20: 1167-1174. 10.1200/JCO.20.5.1167CrossRefPubMed Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20: 1167-1174. 10.1200/JCO.20.5.1167CrossRefPubMed
4.
go back to reference Kawaguchi Y, Nishiyama K, Miyagi K, Suzuki O, Ito Y, Nakamura S: Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 2011, 41: 1007-1012. 10.1093/jjco/hyr069CrossRefPubMed Kawaguchi Y, Nishiyama K, Miyagi K, Suzuki O, Ito Y, Nakamura S: Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 2011, 41: 1007-1012. 10.1093/jjco/hyr069CrossRefPubMed
5.
go back to reference Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012, 118: 2632-2640. 10.1002/cncr.26586PubMedCentralCrossRefPubMed Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W, Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 2012, 118: 2632-2640. 10.1002/cncr.26586PubMedCentralCrossRefPubMed
6.
go back to reference Zhao KL, Ma JB, Liu G, Wu KL, Shi XH, Jiang GL: Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys 2010, 76: 446-451. 10.1016/j.ijrobp.2009.02.078CrossRefPubMed Zhao KL, Ma JB, Liu G, Wu KL, Shi XH, Jiang GL: Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys 2010, 76: 446-451. 10.1016/j.ijrobp.2009.02.078CrossRefPubMed
7.
go back to reference Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003, 21: 2697-2702. 10.1200/JCO.2003.03.055CrossRefPubMed Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T, Yoshida S: Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003, 21: 2697-2702. 10.1200/JCO.2003.03.055CrossRefPubMed
8.
go back to reference Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-216. 10.1093/jnci/92.3.205CrossRefPubMed Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-216. 10.1093/jnci/92.3.205CrossRefPubMed
9.
go back to reference Rice TW, Rusch VW, Ishwaran H, Blackstone EH: Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010, 116: 3763-3773. 10.1002/cncr.25146CrossRefPubMed Rice TW, Rusch VW, Ishwaran H, Blackstone EH: Worldwide Esophageal Cancer Collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010, 116: 3763-3773. 10.1002/cncr.25146CrossRefPubMed
10.
go back to reference Uno T, Isobe K, Kawakami H, Ueno N, Kobayashi H, Shimada H, Mastubara H, Okazumi S, Nabeya Y, Shiratori T, Ochiai T, Kawata T, Ito H: Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer. Anticancer Res 2004, 24: 2483-2486.PubMed Uno T, Isobe K, Kawakami H, Ueno N, Kobayashi H, Shimada H, Mastubara H, Okazumi S, Nabeya Y, Shiratori T, Ochiai T, Kawata T, Ito H: Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer. Anticancer Res 2004, 24: 2483-2486.PubMed
11.
go back to reference Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino T: Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 2009, 92: 266-269. 10.1016/j.radonc.2008.09.025CrossRefPubMed Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino T: Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol 2009, 92: 266-269. 10.1016/j.radonc.2008.09.025CrossRefPubMed
12.
go back to reference Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, Yamada T, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Matsunaga T, Imaoka S: Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus 2006, 19: 73-77. 10.1111/j.1442-2050.2006.00543.xCrossRefPubMed Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, Yamada T, Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Matsunaga T, Imaoka S: Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus 2006, 19: 73-77. 10.1111/j.1442-2050.2006.00543.xCrossRefPubMed
13.
go back to reference Watanabe M, Nishida K, Kimura Y, Miyazaki M, Baba H: Salvage lymphadenectomy for cervical lymph node recurrence after esophagectomy for squamous cell carcinoma of the thoracic esophagus. Dis Esophagus 2012, 25: 62-66. 10.1111/j.1442-2050.2011.01215.xCrossRefPubMed Watanabe M, Nishida K, Kimura Y, Miyazaki M, Baba H: Salvage lymphadenectomy for cervical lymph node recurrence after esophagectomy for squamous cell carcinoma of the thoracic esophagus. Dis Esophagus 2012, 25: 62-66. 10.1111/j.1442-2050.2011.01215.xCrossRefPubMed
14.
go back to reference Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, Baretton GB, Saeger HD: Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009, 24: 886-895. 10.1111/j.1440-1746.2008.05732.xCrossRefPubMed Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, Baretton GB, Saeger HD: Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009, 24: 886-895. 10.1111/j.1440-1746.2008.05732.xCrossRefPubMed
15.
go back to reference Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, Siewert JR, Schroeder M, Makoski HB, Schmidt U, Seeber S, Vanhoefer U: Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005, 131: 67-72. 10.1007/s00432-004-0604-5CrossRefPubMed Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, Siewert JR, Schroeder M, Makoski HB, Schmidt U, Seeber S, Vanhoefer U: Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol 2005, 131: 67-72. 10.1007/s00432-004-0604-5CrossRefPubMed
16.
go back to reference Zhong Z, Gu X, Zhang Z, Wang D, Qing Y, Li M, Dai N: Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. Br J Radiol 2012,85(1019):e1104-e1109. 10.1259/bjr/15321801PubMedCentralCrossRefPubMed Zhong Z, Gu X, Zhang Z, Wang D, Qing Y, Li M, Dai N: Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus. Br J Radiol 2012,85(1019):e1104-e1109. 10.1259/bjr/15321801PubMedCentralCrossRefPubMed
17.
go back to reference Piessen G, Briez N, Triboulet JP, Mariette C: Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery? Ann Surg Oncol 2007, 14: 2036-2044. 10.1245/s10434-007-9405-9CrossRefPubMed Piessen G, Briez N, Triboulet JP, Mariette C: Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery? Ann Surg Oncol 2007, 14: 2036-2044. 10.1245/s10434-007-9405-9CrossRefPubMed
18.
go back to reference Murakami M, Kuroda Y, Matsusue S, Okamoto Y, Nakajima T, Nishimura S, Kusumi F, Hajiro K, Takeda H: Treatment results of esophageal carcinoma of clinical T3, T4M0: historical comparison between neoadjuvant chemoradiotherapy followed by surgery or definitive radiotherapy and conventional surgery. Oncol Rep 2000, 7: 571-578.PubMed Murakami M, Kuroda Y, Matsusue S, Okamoto Y, Nakajima T, Nishimura S, Kusumi F, Hajiro K, Takeda H: Treatment results of esophageal carcinoma of clinical T3, T4M0: historical comparison between neoadjuvant chemoradiotherapy followed by surgery or definitive radiotherapy and conventional surgery. Oncol Rep 2000, 7: 571-578.PubMed
19.
go back to reference Watanabe M, Nagai Y, Kinoshita K, Saito S, Kurashige J, Karashima R, Hirashima K, Sato N, Imamura Y, Hiyoshi Y, Baba Y, Iwagami S, Miyamoto Y, Iwatsuki M, Hayashi N, Baba H: Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion 2011, 83: 146-152. 10.1159/000321797CrossRefPubMed Watanabe M, Nagai Y, Kinoshita K, Saito S, Kurashige J, Karashima R, Hirashima K, Sato N, Imamura Y, Hiyoshi Y, Baba Y, Iwagami S, Miyamoto Y, Iwatsuki M, Hayashi N, Baba H: Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil for patients with node-positive esophageal cancer. Digestion 2011, 83: 146-152. 10.1159/000321797CrossRefPubMed
20.
go back to reference de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS: The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006, 29: 26-29. 10.1016/j.ejcts.2005.10.002CrossRefPubMed de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS: The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006, 29: 26-29. 10.1016/j.ejcts.2005.10.002CrossRefPubMed
Metadata
Title
Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
Authors
Xiaoli Zhang
Minghuan LI
Xue Meng
Li Kong
Yan Zhang
Guangsheng Wei
Xiqin Zhang
Fang Shi
Man Hu
Guoli Zhang
Jinming Yu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-9-64

Other articles of this Issue 1/2014

Radiation Oncology 1/2014 Go to the issue